𝐽𝑎𝑣𝑖𝑒𝑟 𝑀𝑒𝑟𝑎𝑦𝑜-𝐶ℎ𝑎𝑙𝑖𝑐𝑜 MerayoDr
7 years 4 months ago
#EULAR2019 ⬇️IgG o nl preRTX y ⬇️IgG postRTX ⬆️⬆️⬆️riesgo de infección (RR >15)
Debe de ser mandatorio vigilar Igs en pacientes bajo tx con rituximab @PanlarLeague @eular_org https://t.co/we6G1D4VXu
EULAR | The European League Against Rheumatism eular_org
7 years 4 months ago
Welcome to the second day of the #EULAR2019 Joint Congress with PReS. Check the scientific programme and highlights for your day’s itinerary. https://t.co/KiNEJUcHJI https://t.co/MFt21kDMJs
Dr Irwin Lim _connectedcare
7 years 4 months ago
Osteoporosis Medication. When to stop? When to switch?
I find this hard so here are Swiss guidelines #eular2019 https://t.co/WNhDanIXRg
Dr Irwin Lim _connectedcare
7 years 4 months ago
You speak sense. And I do what you do for steroid-induced osteoporosis prevention. However the convenience of Denosumab is winning at least in Australia. Think Around 80% of market #EULAR2019 https://t.co/nL3BzCon8g
Janet Pope Janetbirdope
7 years 4 months ago
You can taper prednisone for pts doing well on combination or monoRx with Tocilizumab in RA who achieved low disease activity or remission but with slightly more flares in RCT of steroid taper va not. Abstract OP0030 #EULAR2019 @RheumNow https://t.co/Mb1OVtnJ1R
Janet Pope Janetbirdope
7 years 4 months ago
EULAR Madrid is off to a great start. Madrid is not too hot compared to two years ago. Beautiful region to explore. Do you know where this castle from 12th c that inspired Disney castle is? @RheumNow #EULAR2019 https://t.co/N2znTe3EFW
Here are a few of the highlights from day 1 EULAR in Madrid.
At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed.
EULAR | The European League Against Rheumatism eular_org
7 years 4 months ago
Reunite with old friends and extend your professional network at the #EULAR2019 Networking Platform in Hall 6. We hope you are enjoying your evening! https://t.co/zcqx9wHSmU
Many of the great presentations from EULAR 2019 feature industry sponsored clinical trials. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.Below is a collection of the industry press releases detailing the abstracts, authors and presentation times from EULAR 2019.
Dr. Dinesh Khanna sclerodermaUM
7 years 4 months ago
impact on mRSS in abatacept group whereas placebo did change (purple lines). Time for personalized medicine!! #EULAR2019 https://t.co/XmYLq8ddIp
Dr. Dinesh Khanna sclerodermaUM
7 years 4 months ago
Early SSC is very hetogeneous disease. Data from the ASSET trial @bmsnews @UMIntMed and Whitfield lab (funded by @NIAIDNews) shows 1. Skin gene expression can largely be divided into 3 large groups with 41% with Normal like expression!! 2. Patients RX with abatacept had striking
Loreto Carmona 🖖 carmona_loreto
7 years 4 months ago
We don’t take medications either because we can’t or because we don’t want to. Robert Horne on #adherence #EULAR2019 https://t.co/YUdLCfGErV
Dr. John Cush RheumNow
7 years 4 months ago
This was a great presentation - 36K ANA test, 7875 repeat ANAs (11% rheums 82% non-rheums) ~10% each went from Pos to Neg (or Neg to Pos) but only 5 new Rheumatic Dx made - incredibly low yield and low PPV https://t.co/Ng8Fg4k158
